IsoPlexis, a Branford, Conn.-based company focused on advancing single-cell biomarkers to address critical challenges in oncology & beyond, raised $25m in Series C funding.
The round was led by Northpond Ventures with participation from current investors Spring Mountain Capital, Ironwood Capital, North Sound Capital, and Connecticut Innovations.
Led by Sean Mackay, CEO and co-founder, IsoPlexis aims to accelerate the fight against cancer and a range of the world’s toughest diseases with its single-cell detection systems. By revealing unique immune biomarkers in small subsets of cells, the company is advancing immunotherapies and targeted therapies to a more precise & personalized stage. Its integrated systems are used globally to advance the field of single-cell biology and biomarkers.
In 2018, IsoPlexis’ novel single-cell immune biomarkers accelerated insights in the field of cancer immunotherapy. Its single-cell polyfunctional strength product predicted responses of CAR engineered T cell therapy patients in blood cancers, pre-therapy, for the first time.
Customers also released multiple data sets defining the quality of patient response of CAR-T, TCR-T, CRISPR edited T-cells, and more. Additionally, its systems achieved correlative data through its novel profiling of TILs and T-cell from the blood of checkpoint immunotherapy patients.
IsoPlexis rapidly expanded its user base with the launch of the IsoLight system at various Cancer Centers and biopharmas in the US, Europe and China in the second half of 2018.
For 2019, the company has begun to share information on new single-cell product launches to address high need areas based on data generated and published on IsoPlexis’ platform. These include: single-cell polyfunctional inflammation solutions targeted towards neuroinflammation and autoimmunity, single-cell solutions for innate & myeloid cell types that contribute to immunotherapy response, single-cell energy state assays focused on advanced metabolomics in oncology, and tumor resistance assays focused on advanced tumor signaling.
In continuing its path forward, the company continues to utilize its internal application engine and its partnerships with university professors and co-founders to build innovative single-cell products addressing high need disease areas.
Additionally, it will expand its global operational, manufacturing, and commercial team across US, Europe and Asia, to add to the 105 employees IsoPlexis has currently.